Crain's: Man who received ALS stem cell transplant still doing well
Ted Harada, a 40-year-old man diagnosed with ALS, who received stem cell implantations to his spinal cord in two separate surgeries as part of the first-ever FDA-approved trial of a stem cell therapy for ALS, talked last week with Crain's Detroit business reporter Tom Henderson. Harada said he's still feeling the positive effects he attributes to his second surgery, which took place last August.
"I've been doing great and feeling great." Harada told Henderson. "Just now, the left leg showed a little bit of weakness returning, but I'm still so much better than I was before the surgeries. It's the first time, since August, they've noticed any slight weakness.
"It's clear from the data that the injections reversed my symptoms and slowed down the progression of the disease. I've received a blessing. I almost forget I have ALS. I don't have the constant reminder of having to use the canes. Now, I don't think about ALS every day. Every couple of days something happens and I think, `Oh, yeah, I have ALS.' "
Taubman Institute Director Dr. Eva Feldman received FDA approval in April to move the trial to Phase II, which will study efficacy as well as safety. Patient recruitment has not yet started for that phase of the trial.
Click here to read the entire Crain's blog post.
Stem cell symposium set for Sept. 19 in Ann Arbor
Dr. Eva Feldman will be among the speakers at the one-day event, which focuses on cutting-edge developments in stem-cell biology, epigenetics and regneratrive medicine.
Click here for details and registration.
New U-M President visits Taubman Institute
The Institute hosted a fellow clinician-scientist when the University of Michigan’s new president paid a visit to the A. Alfred Taubman Biomedical Science Research Building.
People who care
Institute welcomes new gift officer
Maria Muller has been appointed to work with connect donors with funding opportunities at the Taubman Institute.
Click here to read more.
news & events
Institute symposium set for Oct. 10
The A. Alfred Taubman Medical Research Institute will award the 2014 $100,000 Taubman Prize for Excellence in Translational Medical Science at its 7th annual symposium at 10 a.m. on Oct. 10.
Dr. Carl June, a physician-scientist who developed a personalized immunotherapy for leukemia using patients’ own T cells, will receive the honor and deliver the symposium's keynote address.
Click here for symposium details.
Drug cuts risk of bone-marrow transplant side effect
Taubman Emerging Scholar Sung Won Choi, M.D., is the lead author of a new study that finds a new way to help prevent graft-vs-host disease in cancer patients receiving bone-marrow transplants.
Study: Two types of cancer stem cells lead to metastasis
Breast cancer stem cells exist in two different states and each state plays a role in how cancer spreads, according to a new study published by Taubman Senior Scholar Dr. Max Wicha.